Atturos is a fast-growing clinical diagnostics brand that specializes in developing the next generation of molecular diagnostic tests. Their cutting-edge technology supports clinicians in making informed treatment decisions for patients. As a spin-out company from University College Dublin (UCD), Atturos is built on excellent science with a focus on patient well-being.

Their advanced targeted proteomics methods and machine learning analytics drive the development of diagnostic tests for chronic diseases like inflammatory arthritis, prostate cancer, and diabetic kidney disease. Led by a highly experienced and dedicated leadership team, Atturos leverages an extensive network of commercial, clinical, and scientific advisors. Their proprietary proteomics platform and AI-driven data analytics enable easy interpretation of test results, empowering clinicians and patients to make the best decisions.

Through targeted mass spectrometry, Atturos measures ultra-low protein biomarker concentrations accurately, helping improve patient outcomes. Atturos is dedicated to developing advanced diagnostic solutions that provide certainty in measuring protein biomarkers and aiding in making optimal clinical decisions